{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:00:41Z","timestamp":1777536041147,"version":"3.51.4"},"reference-count":15,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean age 43 (\u00b121) years, with a history of CC-asthma and history of \u22652 exacerbations\/year requiring systemic steroids and\/or antibiotics. All had decreased Streptococcus pneumoniae antibody titers, with a mean average of 3 of 23 normal serotypes and were subsequently vaccinated with PPSV-23. Pre- and post-12-month vaccination questionnaires were administered, and 35 (54%) reported both decreased CC symptoms and asthma medication use. Baseline comparisons to those with no change in CC symptoms or asthma medication use revealed significantly lower exhaled nitric oxide (FeNO) levels (17 \u00b1 10; 62 + 40 ppb), serum eosinophils (192 \u00b1 156; 280 \u00b1 166\/mcL), and total IgE (132 \u00b1 167; 275 \u00b1 290 IU\/mL) in those with improvement post-vaccination. Higher baseline symptoms scores for upper respiratory infections as a trigger to their CC (* p &gt; 0.05) were found in those responding to PPSV-23. These data reveal a subset of asthma in younger adults, &lt;65 years, with significantly decreased S. pneumoniae antibody titers with less CC symptoms and asthma medication use for exacerbations after PPSV-23 vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10020219","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T01:46:21Z","timestamp":1643593581000},"page":"219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering"],"prefix":"10.3390","volume":"10","author":[{"given":"Alessandra M.","family":"Lanz","sequence":"first","affiliation":[{"name":"Allergy, Asthma & Sinusitis, AAADRS Clinical Research Center, Coral Gables, FL 33134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Chartrand","sequence":"additional","affiliation":[{"name":"Allergy, Asthma & Sinusitis, AAADRS Clinical Research Center, Coral Gables, FL 33134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia P.","family":"Eisenlohr","sequence":"additional","affiliation":[{"name":"Allergy, Asthma & Sinusitis, AAADRS Clinical Research Center, Coral Gables, FL 33134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-5596","authenticated-orcid":false,"given":"Miguel J.","family":"Lanz","sequence":"additional","affiliation":[{"name":"Allergy, Asthma & Sinusitis, AAADRS Clinical Research Center, Coral Gables, FL 33134, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2008.07.029","article-title":"Increased risk of serious pneumococcal disease in patients with asthma","volume":"122","author":"Juhn","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2013.07.079","article-title":"Risk of invasive pneumococcal disease in children and adults with asthma","volume":"31","author":"Boikos","year":"2013","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/02770903.2019.1575394","article-title":"Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination","volume":"57","author":"Sheen","year":"2020","journal-title":"J. Asthma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-017-0200-2","article-title":"A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine","volume":"13","author":"Laratta","year":"2017","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106207","DOI":"10.1016\/j.rmed.2020.106207","article-title":"Use of Pneumococcal and influenza vaccine in patients with COPD, asthma and interstitial lung diseases in Germany","volume":"174","author":"Mohr","year":"2020","journal-title":"Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jaip.2021.10.032","article-title":"2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges","volume":"10","author":"Chipps","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"Akdis","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-020-00903-x","article-title":"Th17\/IL-17 Axis Regulated by Airway Microbes Get Involved in the Development of Asthma","volume":"20","author":"Liu","year":"2020","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.129.1_suppl.1S","article-title":"Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Irwin","year":"2006","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e20191200","DOI":"10.1542\/peds.2019-1200","article-title":"Asthma and the risk of invasive pneumococcal disease","volume":"145","author":"Abarca","year":"2020","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/iid3.331","article-title":"Impact of pneumococcal vaccine response on asthma exacerbation frequency in young children","volume":"8","author":"Eisenlohr","year":"2020","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1086\/374624","article-title":"Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential","volume":"187","author":"Brueggemann","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1128\/CVI.00259-14","article-title":"Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential","volume":"21","author":"Athlin","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_15","first-page":"27","article-title":"A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J. Pediatr. Pharmacol. Ther."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:24Z","timestamp":1760134284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020219"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020219","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]}}}